Meta-analysis of overall response rate for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

Zhang Xunlei
Cao Chunxiang
Zhang Qi
Chen Yi
Gu Dongying
Shen Yunzhu
Gong Yongling
Chen Jinfei
Tang Cuiju

January 2014

Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regime...

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patients.

Marilyn D. Skinner (521507)
Pierre Lahmek (521508)
Héloïse Pham (521509)
Henri-Jean Aubin (370879)

February 2014

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patient...

Meta-analysis of progression free survival data by chemotherapy regimen.

Irena Ilic (647686)
Slobodan Jankovic (3139815)
Milena Ilic (647685)

August 2016

Abbreviations: SE = Standard Error; 95% CI = 95% Confidence Interval; Chi2 = Chi-squar...

Meta-analysis of overall survival for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of overall survival for S-1-based chemotherapy compared with capecitabine-based che...

Meta-analysis of time to progression for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of time to progression for S-1-based chemotherapy compared with capecitabine-based ...

Meta-analysis of 0.5-year, 1-year, and 2-year survival probability for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of 0.5-year, 1-year, and 2-year survival probability for S-1-based chemotherapy com...

Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).

André Bacellar Costa Lima (346937)
Ligia T. Macedo (346938)
André Deeke Sasse (346939)

February 2013

Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).</p

Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard therapy in all trials combined.

Fariba Ahmadizar (791472)
N. Charlotte Onland-Moret (113650)
Anthonius de Boer (179500)
Geoffrey Liu (331900)
Anke H. Maitland-van der Zee (791473)

September 2015

Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard ther...

Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-Clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

July 2015

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

SYSTEMATIC REVIEW Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Penn State
Milton S. Joseph
J. Drabick
Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

January 2016

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

SYSTEMATIC REVIEW Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Penn State
Milton S. Joseph
J. Drabick
Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

August 2016

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.

Ashdown, ML
Robinson, AP
Yatomi-Clarke, SL
Ashdown, ML
Allison, A
Abbott, D
Markovic, SN
Coventry, BJ

January 2015

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

August 2016

Background: Although both oral fluoropyrimidines were reported effective and safe, doubts exist abou...

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

He Ming-ming
Wu Wen-jing
Wang Feng
Wang Zhi-qiang
Zhang Dong-sheng
Luo Hui-yan
Qiu Miao-zhen
Wang Feng-hua
Ren Chao
Zeng Zhao-lei
Xu Rui-hua

December 2013

Although both oral fluoropyrimidines were reported effective and safe, doubts exist about whether S-...

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

Zhang Xunlei
Cao Chunxiang
Zhang Qi
Chen Yi
Gu Dongying
Shen Yunzhu
Gong Yongling
Chen Jinfei
Tang Cuiju

January 2014

Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regime...

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

Zhang Xunlei
Cao Chunxiang
Zhang Qi
Chen Yi
Gu Dongying
Shen Yunzhu
Gong Yongling
Chen Jinfei
Tang Cuiju

January 2014

Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regime...

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patients.

Marilyn D. Skinner (521507)
Pierre Lahmek (521508)
Héloïse Pham (521509)
Henri-Jean Aubin (370879)

February 2014

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patient...

Meta-analysis of progression free survival data by chemotherapy regimen.

Irena Ilic (647686)
Slobodan Jankovic (3139815)
Milena Ilic (647685)

August 2016

Abbreviations: SE = Standard Error; 95% CI = 95% Confidence Interval; Chi2 = Chi-squar...

Meta-analysis of overall survival for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of overall survival for S-1-based chemotherapy compared with capecitabine-based che...

Meta-analysis of time to progression for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of time to progression for S-1-based chemotherapy compared with capecitabine-based ...

Meta-analysis of 0.5-year, 1-year, and 2-year survival probability for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Ming-ming He (496649)
Wen-jing Wu (390400)
Feng Wang (44414)
Zhi-qiang Wang (3117885)
Dong-sheng Zhang (5651446)
Hui-yan Luo (286730)
Miao-zhen Qiu (286719)
Feng-hua Wang (286734)
Chao Ren (286724)
Zhao-lei Zeng (390399)
Rui-hua Xu (286736)

December 2013

Meta-analysis of 0.5-year, 1-year, and 2-year survival probability for S-1-based chemotherapy com...

Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).

André Bacellar Costa Lima (346937)
Ligia T. Macedo (346938)
André Deeke Sasse (346939)

February 2013

Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).</p

Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard therapy in all trials combined.

Fariba Ahmadizar (791472)
N. Charlotte Onland-Moret (113650)
Anthonius de Boer (179500)
Geoffrey Liu (331900)
Anke H. Maitland-van der Zee (791473)

September 2015

Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard ther...

Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-Clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

July 2015

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

SYSTEMATIC REVIEW Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Penn State
Milton S. Joseph
J. Drabick
Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

January 2016

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

SYSTEMATIC REVIEW Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates [version 1; referees: 2 approved]

Penn State
Milton S. Joseph
J. Drabick
Martin L. Ashdown
Andrew P. Robinson
Steven L. Yatomi-clarke
M. Luisa Ashdown
Andrew Allison
Derek Abbott
Svetomir N. Markovic
Brendon J. Coventry

August 2016

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.

Ashdown, ML
Robinson, AP
Yatomi-Clarke, SL
Ashdown, ML
Allison, A
Abbott, D
Markovic, SN
Coventry, BJ

January 2015

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are ...

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

August 2016

Background: Although both oral fluoropyrimidines were reported effective and safe, doubts exist abou...

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

He Ming-ming
Wu Wen-jing
Wang Feng
Wang Zhi-qiang
Zhang Dong-sheng
Luo Hui-yan
Qiu Miao-zhen
Wang Feng-hua
Ren Chao
Zeng Zhao-lei
Xu Rui-hua

December 2013

Although both oral fluoropyrimidines were reported effective and safe, doubts exist about whether S-...

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

Zhang Xunlei
Cao Chunxiang
Zhang Qi
Chen Yi
Gu Dongying
Shen Yunzhu
Gong Yongling
Chen Jinfei
Tang Cuiju

January 2014

Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regime...

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

Zhang Xunlei
Cao Chunxiang
Zhang Qi
Chen Yi
Gu Dongying
Shen Yunzhu
Gong Yongling
Chen Jinfei
Tang Cuiju

January 2014

Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regime...

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patients.

Marilyn D. Skinner (521507)
Pierre Lahmek (521508)
Héloïse Pham (521509)
Henri-Jean Aubin (370879)

February 2014

Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patient...

Meta-analysis of progression free survival data by chemotherapy regimen.

Irena Ilic (647686)
Slobodan Jankovic (3139815)
Milena Ilic (647685)

August 2016

Abbreviations: SE = Standard Error; 95% CI = 95% Confidence Interval; Chi2 = Chi-squar...

Meta-analysis of overall response rate for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Abstract

Extracted data

Meta-analysis of overall response rate for S-1-based chemotherapy compared with capecitabine-based chemotherapy.

Abstract

Extracted data

Related items

Related items